BRCA1 and ovarian cancer: Here, we identified a small molecule SN-38, which could inhibit HR repair activity in ovarian cancer cells and verified the synergistic antitumor effects of SN-38 and olaparib combination in BRCA1/2-proficient ovarian cancer cells.